[et_pb_section admin_label=”section”]
\n\t\t\t[et_pb_row admin_label=”row”]
\n\t\t\t\t[et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]The Hospital General Universitario Gregorio Mara\u00f1\u00f3n, the hospital to which this group belongs, has
\nextensive experience within the multidisciplinary cancer unit in the treatment of this disease in its different stages.
\ndifferent stages.
\nThe generic objective of research in the Oncology Area is to generate reliable and scientifically relevant information on the
\nindividualized cancer treatment, through translational research, which may allow for the selection of the most appropriate
\nantitumor treatment that provides more curative options and fewer sequelae for each patient. The selection
\nThe therapy will be based essentially on the genetic\/molecular profile of the patient and the tumor. The selection
\nThe appropriate selection of cancer patients who are candidates for sophisticated antitumor therapies (target medical treatments),
\nhigh-definition radiotherapy, cell therapy, hemopoietic progenitor transplantation) available at our facilities.
\ncenter, will allow the most suitable choice to be made for each patient. In addition, the Area will study the cancer syndromes
\nand other high-risk cancer situations, in which a variety of interventions can be used to prevent cancer in the family and in other high-risk situations.
\ncan be very effective in reducing the likelihood of disease occurrence.
\nThe research group has a Clinical and Translational Research Unit integrated within the Department of
\nMedical Oncology, which is developing clinical trials in digestive tumors with new antitumor agents, and
\ntechnologies. It also has a Translational Oncology Laboratory (LAOT), which has been equipped to perform the following tests
\ngenomic studies, also counting with the technology of the sequencing and genotyping unit and equipped with
\nfor the development of cell biology techniques. It also features immunomagnetic separation technology.
\non microfluidic support (IsofluxTM, FluxionBiosciences, Inc.), which in its performance indicates the increase of the
\nsignificant of the number of isolated CTCs, independent of EpCAM expression levels. With this
\ntechnology will be able to perform CTCs enumeration from liquid biopsy. This technology allows its application
\nin the counting and recovery of CTCs. In addition, the Hospital has an Animal Unit which provides
\nlogistical support to researchers in order to carry out the entire xenotransplantation technology.
\nStrategic Axes
\n1. Strengthen alliances and collaborations in oncology.
\n2. Consolidation of research lines in oncology.
\n3. Training
\n4. Infrastructure consolidation
\nExamples of Lines of Research
\nValue of liquid biopsy as a predictor of response in oncology patients.
\n1. Development of preclinical models and PDXs
\n2. Organoid Development
\n3. Search for genomic profiles as predictors of response in the oncology patient
\n4. Immunotherapy for cancer disease.
\n5. Predictive models of thrombosis risk in patients with pancreatic cancer.
\n6. Predictive models of survival in pancreatic cancer (development of a prognostic score with 3 variables: hemoglobin, platelets and leukocytes).[\/et_pb_text][\/et_pb_column]
\n\t\t\t[\/et_pb_row]
\n\t\t[\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]The Hospital General Universitario Gregorio Mara\u00f1\u00f3n, the hospital to which this group belongs, has extensive experience within the multidisciplinary cancer unit in the treatment of this disease in its different stages. different stages. The generic objective of research in the Oncology Area is to generate reliable and scientifically relevant […]<\/p>\n","protected":false},"featured_media":1465,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"The Hospital General Universitario Gregorio Mara\u00f1\u00f3n, the hospital to which this group belongs, has\nextensive experience within the multidisciplinary cancer unit in the treatment of this disease in its different stages.\ndifferent stages.\nThe generic objective of research in the Oncology Area is to generate reliable and scientifically relevant information on the\nindividualized cancer treatment, through translational research, which may allow for the selection of the most appropriate\nantitumor treatment that provides more curative options and fewer sequelae for each patient. The selection\nThe therapy will be based essentially on the genetic\/molecular profile of the patient and the tumor. The selection\nThe appropriate selection of cancer patients who are candidates for sophisticated antitumor therapies (target medical treatments),\nhigh-definition radiotherapy, cell therapy, hemopoietic progenitor transplantation) available at our facilities.\ncenter, will allow the most suitable choice to be made for each patient. In addition, the Area will study the cancer syndromes\nand other high-risk cancer situations, in which a variety of interventions can be used to prevent cancer in the family and in other high-risk situations.\ncan be very effective in reducing the likelihood of disease occurrence.\nThe research group has a Clinical and Translational Research Unit integrated within the Department of\nMedical Oncology, which is developing clinical trials in digestive tumors with new antitumor agents, and\ntechnologies. It also has a Translational Oncology Laboratory (LAOT), which has been equipped to perform the following tests\ngenomic studies, also counting with the technology of the sequencing and genotyping unit and equipped with\nfor the development of cell biology techniques. It also features immunomagnetic separation technology.\non microfluidic support (IsofluxTM, FluxionBiosciences, Inc.), which in its performance indicates the increase of the\nsignificant of the number of isolated CTCs, independent of EpCAM expression levels. With this\ntechnology will be able to perform CTCs enumeration from liquid biopsy. This technology allows its application\nin the counting and recovery of CTCs. In addition, the Hospital has an Animal Unit which provides\nlogistical support to researchers in order to carry out the entire xenotransplantation technology.\nStrategic Axes\n1. Strengthen alliances and collaborations in oncology.\n2. Consolidation of research lines in oncology.\n3. Training\n4. Infrastructure consolidation\nExamples of Lines of Research\nValue of liquid biopsy as a predictor of response in oncology patients.\n1. Development of preclinical models and PDXs\n2. Organoid Development\n3. Search for genomic profiles as predictors of response in the oncology patient\n4. Immunotherapy for cancer disease.\n5. Predictive models of thrombosis risk in patients with pancreatic cancer.\n6. Predictive models of survival in pancreatic cancer (development of a prognostic score with 3 variables: hemoglobin, platelets and leukocytes).","_et_gb_content_width":"","inline_featured_image":false},"investigacion":[54],"class_list":["post-1466","grupo","type-grupo","status-publish","has-post-thumbnail","hentry","investigacion-clinical"],"_links":{"self":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/grupo\/1466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/grupo"}],"about":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/types\/grupo"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/media\/1465"}],"wp:attachment":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/media?parent=1466"}],"wp:term":[{"taxonomy":"investigacion","embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/investigacion?post=1466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}